FDA shapes carrot & stick inspections plan; asserts no India ''agenda''
This article was originally published in Scrip
Executive Summary
Pharmaceutical firms that pose minimal quality compliance risks could potentially attract a reduced frequency of inspections by the FDA under the agency's proposed new "carrot and stick" approach to facility audits.